Description
Irsogladine exhibits anti-inflammatory, anti-fibrotic, and mucoprotective activities. Irsogladine decreases non-steroidal anti-inflammatory drug (NSAID)-induced intestinal mucosal injury, ulcers, and esophagitis; it inhibits COX-1 and COX-2. In animal models of colitis, irsogladine prevents DDS-induced increases in TGF-β1, collagen type 1, MMP2, TIMP-1, and α-SMA, preventing fibrosis. Additionally, irsogladine non-selectively inhibits phosphodiesterases, increasing cAMP and NO, facilitating gap junction communication and altering gastric mucosal blood flow.
References
Kuramoto T, Umegaki E, Nouda S, et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol. 2013 May 14;13:85. PMID: 23672202.
Akagi M, Amagase K, Murakami T, et al. Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. Curr Pharm Des. 2013;19(1):106-14. PMID: 22950502.
Yamaguchi H, Suzuki K, Nagata M, et al. Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium. Med Mol Morphol. 2012 Jun;45(3):140-51. PMID: 23001296.
